Christopher Murriel | Senior Scientist of Cancer Biology
Oncomed Pharmaceuticals

Appearances:

Day 2 Antibody Congress @ 16:21

Clinical update: targeting DLL4 and Notch 2/3 to inhibit tumors

Plenary

• An update on OncoMed’s clinical development of antibodies targeting DLL4 and Notch2/3
• Blocking DLL4 has been shown in preclinical studies to result in anti-tumor activity via multiple mechanisms, including inhibiting cancer stem cell growth and promoting cell differentiation, disrupting angiogenesis and potentially enhancing anti-tumor immune response.
• Tarextumab (anti-Notch2/3, OMP-59R5) is a novel anti-cancer stem cell antibody that prevents signaling through both the Notch2 and Notch3 receptors. Tarextumab has been shown in preclinical models to inhibit cancer stem cell growth, and promote cell differentiation, as well as disrupt tumor angiogenesis by inhibiting vascular pericytes.

Christopher Murriel, Senior Scientist of Cancer Biology, Oncomed Pharmaceuticals